The STEP 6 findings reveal significant weight loss, along with a reduction in abdominal visceral fat, in east Asian people with obesity taking a high dose of semaglutide.
Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.
A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.
More on GLP-1 receptor agonists
04-06-2022 | ADA 2022 | Conference coverage | News